Online inquiry

IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13284MR)

This product GTTS-WQ13284MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1715MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ10668MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ12197MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ2094MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ12153MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ12536MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ6858MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ2394MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW